107

In September 2024, the Australian Government published the final report of the Health Technology Assessment (HTA) Policy and Methods Review. On the surface, it is a national reform document. In reality, it is something more consequential: a detailed signal of how a mature HTA system is trying to adapt to a world of gene therapies, biomarker-led care, linked diagnostic–therapeutic propositions, digital platforms, and evidence that no longer arrives in neat, trial-bound packages. The review does not merely propose administrative improvement. It sets out a broader redesign of how Australia will think about access, evidence, uncertainty, equity, transparency, and institutional capability.

The review is unusually explicit about its purpose. Its 50 recommendations are framed around four overarching aims: addressing inequities in access, improving timely access, improving engagement, and investing in HTA capability so the system is adaptable and “futureproof.” That framing matters. It means the reform is not simply about making a slow system faster. It is about building a more proportionate, coherent, and resilient one. The recommendations summary and full recommendations also make clear that this is meant to apply across medicines, vaccines, medical technologies and services, not just pharmaceuticals.

For global MedTech, diagnostics, digital health, and precision-medicine companies, this matters for at least three reasons. First, Australia is confronting the same structural pressures now facing most advanced health systems: the technologies entering care pathways are becoming more complex than the methods used to evaluate them. Second, the review is explicitly broader than pharmaceuticals, spanning the PBS, MBS, National Immunisation Program and Life Saving Drugs Program. Third, because Australia has historically been one of the intellectual reference points for formal economic evaluation in reimbursement policy, changes in its HTA logic are worth reading as an early indicator of where other systems may go next. Ramagopalan’s 2025 commentary makes exactly this point, situating the reform in the context of evolving HTA for cell and gene therapies, inequity, and real-world evidence.

The deeper issue: not whether technologies work, but whether systems know how to pay for them

In modern healthcare, innovation rarely fails because the underlying science is obviously wrong. More often, it stalls because the system cannot classify its value with enough confidence to fund it. A diagnostic may improve treatment selection without directly generating health gain on its own. A digital platform may reduce admissions only after workflow redesign. A gene therapy may carry very high upfront cost with benefits that unfold over many years. An AI tool may improve triage accuracy, but only under specific implementation conditions. These technologies are not easily described by the older template of “one product, one trial package, one comparator, one budget-impact story.”

That is the quiet but fundamental problem the review is trying to solve. The official documents emphasise that Australia’s current pathways contain complexity, duplication, fragmentation, and inconsistent assessment effort across different types of technologies and funding routes. Different pathways can be triggered by technology type or care setting rather than by what the assessment actually needs to answer, which can create inconsistency, duplication, and unnecessary time burden. At the same time, relatively low-risk or straightforward submissions can still be forced through machinery designed with more complex cases in mind.

This is why Recommendation 3 matters so much. It is not just one recommendation among 50; it is the organising principle. The review states that health-technology funding and assessment processes should be fit-for-purpose and proportionate to the level of clinical benefit, clinical need, complexity, and financial risk; they should be streamlined and simplified; and they should move toward a more unified pathway and committee approach with less duplication between routes. Several later recommendations are explicitly designed to operate in line with this principle. Proportionality is therefore the backbone of the reform logic rather than rhetorical garnish.

HTA in economic terms: this is about scarcity as much as science

It is worth stating plainly what HTA is doing. HTA is not simply scientific review. It is comparative decision-making under scarcity. In Australia, as elsewhere, the core question is whether a new technology improves outcomes, safety, or patient experience sufficiently, and at a cost that is reasonable relative to alternatives and affordable to the community. That is why cost-effectiveness, cost-utility analysis, comparator selection, discounting, and uncertainty analysis sit at the centre of the process. The economics are not incidental. They are the mechanism by which a public system converts clinical evidence into funding choices that are meant to be fair and sustainable. The consultation and methods materials define HTA in precisely these comparative and economic terms.

The review does not retreat from that discipline. What it does is acknowledge that the objects being evaluated have changed. The final report and associated methods work point to the need to modernise how Australia handles technologies with long-dated benefits, immature evidence, pathway-level value, and indirect effects. That is why the review includes recommendations on discount rates, comparator and cost-minimisation principles, valuation and pricing, and a forward methods-development agenda. The reform is not moving away from economic evaluation. It is trying to make it more scientifically credible for newer categories of technology.

Ramagopalan’s 2025 commentary is especially useful here. It notes that the reform agenda includes updated guidance on non-randomised evidence, surrogate endpoints, biomarker-driven and tumour-agnostic therapies, and patient-reported outcomes, together with a larger role for real-world data and real-world evidence. It also highlights the proposal to reduce the base-case discount rate from 5% toward a lower level for technologies whose costs are upfront and benefits accrue over long periods.

That last point deserves more precision, because it is one of the clearest methodological shifts in the whole package. Recommendation 39 explicitly supports reducing the base-case discount rate to no lower than 3.5% for technologies with upfront costs and long-term benefits, such as gene therapies and some vaccines, while other technologies would remain at 5% unless further reform occurs. That is not a vague methodological conversation; it is a concrete recommendation with direct implications for cost-effectiveness results in high-impact technology classes.

That shift is scientifically important. It means the conversation is moving from a narrow question — does the current dossier satisfy the traditional template? — to a more serious one: what mix of evidence, methods, and post-launch learning is defensible for a technology of this type?

The methods engine room: technical papers matter here

One of the things that makes the Australian review more than a rhetorical reform exercise is that it was supported by a set of dedicated technical papers. These covered, among other things, economic evaluation, real-world data and real-world evidence, emerging health technologies, and pathways and timelines. The economic-evaluation paper addresses issues such as cost-effectiveness and cost-utility analysis, uncertainty, discounting, and evolving evidentiary challenges. The review therefore has an identifiable methodological engine room rather than just a high-level policy shell.

That matters for readers in industry. It shows that the reform is not just saying “be more flexible.” It is trying to define where flexibility is scientifically justifiable and where standards still need to be maintained.

Real-world evidence is moving from supplement to infrastructure

Many policy documents speak warmly about real-world evidence. Australia’s review goes further by giving it operational shape.

The final report proposes that Australia should develop and implement a framework to optimise timely access to relevant, high-quality real-world data for HTA and to supplement available randomised trial evidence. It recommends a coordinated, multi-stakeholder approach to transparent evidence-development planning, early identification of data collections that could resolve key uncertainties, and explicit use of post-listing evidence where technologies are likely to enter managed arrangements. These are not vague endorsements of better data. They amount to a structural repositioning of RWD/RWE within HTA.

The significance is clearest if we separate three roles for real-world evidence.

First, RWE can help reduce pre-decision uncertainty where trial evidence is incomplete, impractical, or structurally limited, especially in small populations, precision settings, or rapidly evolving technologies.

Second, it can support conditional, managed, or staged access, where funding is linked to continued evidence development rather than a pretence of full certainty at launch.

Third, it can create a feedback loop for reassessment, allowing cost-effectiveness estimates, utilisation forecasts, and real-world performance assumptions to be updated over time.

The review material and Ramagopalan’s summary of the emerging implementation agenda clearly point in this direction.

It is also worth being clear that this is not an invitation to treat any observational dataset as automatically decision-grade. The associated technical work and the broader literature imply minimum conditions for RWE to be credible in HTA: fit-for-purpose study design, transparent protocols, appropriate control of confounding and bias, endpoints aligned with the decision problem, and data quality sufficient for economic and utilisation modelling. In other words, the reform signals that RWE is expected to meet standards, not merely exist.

This matters especially for MedTech and diagnostics. Technologies whose value emerges only after deployment into practice are often disadvantaged if HTA treats launch evidence as the whole story. Australia appears to be edging toward a model in which launch is the beginning of a structured evidence trajectory, not the end of it.

Timeliness: the reform is about choreography, not just speed

Key Components of the Australian HTA Reform (2024 2026)

The politics of access are often narrated as impatience with bureaucracy. The more interesting reality is that delay is usually produced by system design. Regulatory review, HTA review, listing decisions, committee sequencing, duplicated evidentiary steps, and administrative hand-offs all contribute. The review repeatedly raises concern about pathways and timelines and about the burden created by multi-stage processes that do not always align with the actual complexity or risk of the case.

That is where parallel and staged processes come in. Gao and colleagues’ analysis of Australia’s parallel regulatory and reimbursement process for cancer medicines shows that aligning regulatory and HTA steps can shorten the time to funding recommendations, but also that significant latency can remain where post-committee listing and implementation steps are slow. Timeliness, in other words, has at least three components: alignment between regulatory and HTA stages, redesign of internal HTA processes so that requirements are proportionate, and attention to downstream post-committee steps that still slow access even after a positive recommendation.

The HTA Review Implementation Advisory Group makes this more concrete. Its interim report groups the recommendations into five implementation focus areas, including modernised assessment pathways, and discusses streamlined processes, more efficient use of time and data, and pilot arrangements that could reduce unnecessary duplication for particular categories of technologies. It also records regular meetings since early 2025 and a phased work plan towards a final report and roadmap by January 2026.

That language matters because it shows the reform has moved beyond aspiration. The rules are not yet remade, but the sequencing work is already under way.

Diagnostics, MedTech, digital health, and precision medicine: where the reform becomes strategically interesting

Much public commentary still treats HTA reform as if it were mainly about medicines. That misses the more strategically interesting part.

Australia’s review documents are explicit that the scope includes medicines, vaccines, medical technologies and services, and that the public funding architecture includes not just the PBS but the MBS, codependent PBS–MBS technologies, the NIP, the LSDP, and related pathways. The final report notes that the existing arrangements can create fragmentation where different funding routes and committees are triggered by care setting or product category rather than by the underlying clinical and evidentiary logic of the proposition.

This is particularly important for codependent and linked technologies. The report specifically identifies PBS–MBS codependent technologies as part of the current landscape, and the full recommendations describe movement toward a more unified pathway and committee approach intended to reduce fragmentation in care pathways. Ramagopalan’s commentary also notes implementation attention to technologies that currently require both PBAC and MSAC-type assessment logic. That is highly relevant to diagnostics, pathology-linked care, genomic testing, and precision platforms whose value lies in treatment selection or pathway optimisation rather than in direct therapeutic effect alone.

This is why the reform matters so much for diagnostics. Diagnostics generate mediated value. They may reduce time to diagnosis, improve patient stratification, avoid ineffective therapy, reduce hospital utilisation, or support targeted use of expensive treatments. Traditional cost-effectiveness frameworks can underestimate that value if they are not designed to capture pathway effects. Australia’s reform is important because it does not merely imply that this problem exists; it explicitly pushes toward more coherent and proportionate arrangements capable of handling exactly these sorts of propositions.

Digital health and AI face similar challenges. Their performance is often dynamic, implementation-sensitive, and dependent on workflow context. A static evidentiary template is rarely enough. That is one reason the review’s methodological expansion — including greater tolerance for non-randomised evidence under appropriate conditions and stronger RWE infrastructure — is so relevant to digital and AI products as well as to devices and diagnostics.

Equity has moved from rhetoric to mechanism

One of the strongest and most distinctive aspects of the reform is the way equity is being embedded institutionally rather than simply celebrated rhetorically.

The official documents make equity one of the review’s primary aims. More specifically, Recommendation 1 proposes a more equitable system for First Nations people, including creation of a First Nations advisory structure with formal links into PBAC- and MSAC-related processes. The summary recommendations also foreground inequities affecting children and people in rural and remote settings. Equity is being treated as a design principle of HTA policy, not an afterthought.

That is a serious shift. Traditional HTA has often been strongest when measuring aggregate efficiency: cost per QALY, average effect, total budget impact. Equity asks different questions. Who gains? Who is excluded by current evidence rules? Which communities are disadvantaged by standard pathways? Which technologies are clinically valuable precisely because they address populations historically poorly served by mainstream models of evidence and access?

The Australian reform does not claim to answer these questions neatly. But it does something important: it makes them structurally visible in governance, methods, and process design. Supporting literature on operationalising equity in HTA deliberation in Australia points in the same direction, arguing for more explicit consideration of distributional consequences and who benefits from funding decisions.

That has implications for sponsors. Claims around First Nations health, paediatric unmet need, rare disease, remote access, and service inequity are likely to matter more when they are embedded in the logic of reform rather than left as peripheral advocacy.

Transparency and engagement are being treated as design problems, not public-relations problems

Marcus Sellars and colleagues’ qualitative study is valuable because it shows HTA committee work as a human, deliberative process shaped by evidentiary rigour, commercial confidentiality, stakeholder expectations, and public accountability. Their work explores how decision-makers experience committee processes and how competing pressures can complicate recommendations on subsidising new technologies.

The Australian review’s response is not simply to call for nicer communication. It recommends clearer process descriptions, stronger publication practices, more accessible consumer-facing information, and better support for consumer evidence and engagement. The summary and final-report material frame transparency and engagement as part of how the system itself should work, not as after-the-fact explanation.

The IAG interim report reinforces that interpretation by making improved transparency and engagement one of its five consolidated focus areas. That matters practically. Better transparency reduces avoidable iteration, helps sponsors understand how evidence will be read, makes submissions more predictable, and can improve the quality of interaction between committees, clinicians, industry, and patient groups. Transparency is being treated as part of process efficiency and institutional legitimacy at the same time.

Workforce and capability: the binding constraint few people discuss

One of the quieter but most important themes in the reform is capability. The final report frames futureproofing partly in terms of institutional and methodological capability, and the IAG interim report explicitly identifies HTA workforce capacity and capability as one of its five implementation focus areas. The interim report says this includes understanding current capacity, identifying gaps, and thinking about the skills needed for emerging technologies, real-world evidence, newer methods, and more complex evaluation environments.

This matters because reform on paper is easier than reform in practice. A system cannot operationalise more sophisticated methods, better use of data, more proportionate pathways, and stronger engagement if it lacks the workforce to execute them. In that sense, capability is not an accessory to reform. It is a precondition for it.

Implementation: the system is not frozen, but neither is it fully remade

One of the easiest mistakes is to overstate implementation. The review has not magically rewritten Australian HTA overnight.

What has happened is more interesting and more realistic. The HTA Review Implementation Advisory Group was established to advise government on prioritisation and sequencing of the recommendations and to develop a roadmap. Its interim report states that it has met regularly since early 2025, developed a phased work plan, and was working toward a final report and roadmap by January 2026. It consolidates the recommendations into five implementation focus areas: improved access and equity, greater transparency and engagement, modernised assessment pathways, better data and evidence, and building HTA workforce capacity and capability. Government materials also stress that the IAG is advisory and that recommendations still require formal government decisions.

That is what serious reform looks like at this stage. Not every recommendation has been accepted in final operational form. But there is now a recognisable reform programme with sequencing, interdependencies, and priority workstreams. Companies should stop thinking of the review as a document on a shelf and start thinking of it as an active transition environment.

Why this matters globally

Australia’s reform matters internationally not because every jurisdiction will copy it, but because it crystallises questions that many are already facing.

How much uncertainty should be tolerated at launch? When is non-randomised evidence acceptable? How should surrogate outcomes be treated? What does good assessment look like for biomarker-defined and tumour-agnostic indications? How should systems handle codependent and pathway-based technologies? What is the role of post-market evidence in revisiting earlier decisions? How should equity alter deliberation without collapsing economic discipline?

The Australian reform and the associated commentary literature show a mature system asking those questions explicitly. Its direction also aligns with wider international HTA trends: expanded use of RWE, stronger attention to equity, and methods adaptation for precision therapies, high-impact devices, and pathway-based innovation. That is why global MedTech and diagnostics companies should care. Australia is not only reforming its own machinery; it is helping sketch the next-generation grammar of HTA.

What companies should do now

The practical implication is not simply to monitor the policy. It is to redesign evidence thinking.

Companies should move from thinking in terms of a single submission package to thinking in terms of evidence architecture. That means pre-market comparative evidence where possible, but also an explicit post-launch plan for reducing uncertainty, generating real-world outcomes, tracking utilisation, and documenting equity-relevant performance. Diagnostics companies should be sharper about mediated value: how testing changes treatment choice, reduces waste, supports precision use of therapy, or alters pathway costs. AI and digital-health firms should show not only technical performance but workflow fit, real-world deployment conditions, and service-level effects. MedTech sponsors should expect more structured scrutiny of whether the chosen HTA pathway and evidentiary burden are proportionate to risk, complexity, and claimed benefit.

A concrete example helps. Imagine a biomarker-defined therapy plus companion diagnostic. The old submission mindset would focus mainly on the pivotal trial and an economic model built at launch. The newer mindset implied by this reform is broader: pre-market evidence on test performance, comparative clinical utility, and treatment-effect differentiation; then post-launch registry or linked-data follow-up to monitor utilisation, outcomes, subgroup performance, and equity dimensions over time. That is what evidence architecture looks like in practice.

That is the deeper commercial meaning of the Australian reform. It is not just asking innovators for more data. It is asking them for a more intelligent theory of value.

Conclusion

Australia’s HTA review is not simply a local policy tidy-up. It is a serious attempt to rewrite the relationship between evidence, time, uncertainty, equity, and decision-making in a public funding system.

Its four-part reform logic — equity, timeliness, engagement, and future capability — is already more sophisticated than much of the commentary around it. Its proportionality principle is more important than many readers realise. Its attention to non-randomised evidence, surrogate outcomes, biomarker-defined care, RWE infrastructure, codependent technologies, discount-rate reform for long-horizon benefits, workforce capability, and post-market learning makes it especially relevant to MedTech, diagnostics, genomics, and digital platforms. And the IAG’s work shows that this is no longer merely conceptual; the implementation architecture is being assembled now.

For global health-technology companies, the lesson is straightforward. Understanding Australia’s HTA reform is not optional background reading. It is part of understanding where reimbursement logic itself is going.

1. What is actually being reformed in Australia’s HTA system?

Australia is not just tweaking one committee or updating one set of technical guidelines. The Health Technology Assessment Policy and Methods Review is a system-level reform of how publicly funded health technologies are assessed and translated into patient access across multiple programmes, including the Pharmaceutical Benefits Scheme (PBS), Medicare Benefits Schedule (MBS), National Immunisation Program (NIP) and Life Saving Drugs Program (LSDP). The final report sets out 50 recommendations and frames them around four broad objectives: improving equity of access, improving timely access, improving engagement and transparency, and investing in capability so the system is more adaptable and “futureproof.”

What makes this significant is that the review is not simply arguing that Australia should move faster. It is arguing that the existing architecture is no longer well aligned with the kinds of technologies now entering the system. In other words, the reform is about redesigning the relationship between technology type, evidence type, pathway design, decision-making, and post-listing evidence generation. That is why this matters to MedTech and diagnostics companies, not just pharmaceutical manufacturers.

2. Why are people saying Recommendation 3 is so important?

Because it is effectively the organising principle of the whole reform.

Recommendation 3 sets out the overarching principle that HTA funding and assessment processes should be fit-for-purpose and proportionate to the clinical benefit, clinical need, complexity, and financial risk of the technology. It also pushes for more streamlined and simplified processes and movement toward more unified pathway and committee arrangements with less duplication. Several later recommendations are explicitly written to operate “in line with Recommendation 3,” which shows that proportionality is not just one policy preference among many; it is the structural logic meant to shape everything else.

Why does that matter commercially? Because older HTA systems often force very different technologies through similar machinery. A relatively low-risk submission may face a process designed for a far more uncertain or financially consequential case. Conversely, a highly complex technology may end up assessed within structures not designed for its evidentiary reality. Recommendation 3 is trying to correct that mismatch. For companies, this means the future Australian system may increasingly ask not just “is the evidence good?” but also “what level of evidence, scrutiny and committee architecture is proportionate for this type of proposition?”

3. Is this mainly a pharmaceutical reform, or does it really matter for diagnostics and MedTech?

It really does matter for diagnostics, MedTech, digital health and codependent technologies.

The review scope explicitly spans medicines, vaccines, medical technologies and services, and the official documents repeatedly refer to the PBS, MBS, NIP and LSDP rather than to medicines alone. The final report also discusses fragmentation across current pathways and explicitly recognises PBS–MBS codependent technologies, which is highly relevant to companion diagnostics, genomic testing, pathology-linked services and other propositions that do not fit neatly into a single product silo.

This matters because diagnostics and many devices generate mediated value. Their value often lies not in directly producing health gain on their own, but in changing downstream decisions: selecting patients better, reducing time to diagnosis, avoiding ineffective therapy, shortening admission length, or enabling more precise use of expensive treatments. Traditional cost-effectiveness frameworks can undervalue that if they are too narrowly product-centred. Australia’s reform matters because it is explicitly trying to move toward more coherent and proportionate arrangements that can better handle these pathway-based technologies.

4. What does the reform mean for evidence standards? Is Australia becoming more permissive?

Not exactly more permissive. More methodologically adaptive is the better description.

The reform does not abandon rigour or economic evaluation. Instead, it recognises that the next generation of health technologies often arrives with evidence packages that do not fit the older template perfectly. The final report includes a methods agenda, and the review materials explicitly address subjects such as non-randomised and observational evidence, surrogate endpoints, economic evaluation, uncertainty, and real-world data. Recommendation 35 specifically calls for updates to methods for assessing non-randomised and observational evidence, including clearer handling of indirect comparisons, created control groups, and the conditions under which non-randomised studies can be used to estimate treatment effect.

So the shift is not “Australia will now accept weak evidence.” The shift is that the system is trying to define when newer forms of evidence are scientifically acceptable and how they should be analysed, justified, and presented. That is crucial for rare diseases, biomarker-defined care, tumour-agnostic indications, AI-enabled products, and technologies where conventional RCT evidence will remain limited, delayed, or incomplete. Ramagopalan’s 2025 review of market-access developments highlights exactly these areas: non-randomised evidence, surrogate endpoints, biomarker-driven therapies, patient-reported outcomes, and broader RWE use.

5. Why is real-world evidence such a central part of the reform?

Because Australia is moving from treating RWE as an occasional supplement to treating it as part of the infrastructure of decision-making.

The final report includes a dedicated chapter on enhancing real-world data (RWD) and real-world evidence (RWE), and Recommendations 28 to 31 are especially important. They call for a dynamic, enduring data infrastructure for HTA, mapping of Australian real-world data collections, better intergovernmental data collaboration, transparent methods development for RWD/RWE, and early identification of data collections that could help resolve uncertainty where an application is likely to result in a managed entry agreement.

This has at least three strategic implications. First, RWE may increasingly be used to reduce pre-decision uncertainty when trial evidence is incomplete. Second, it supports managed or staged access, where funding can be linked to continued evidence development rather than a fiction of complete certainty at launch. Third, it creates the possibility of reassessment, where earlier assumptions about cost-effectiveness, utilisation, or real-world outcomes can be updated over time. For diagnostics, digital platforms and MedTech, this is potentially transformative because their value often becomes visible only after implementation in routine care.

6. Does that mean any observational dataset will now be acceptable?

No. The reform points toward broader use of RWE, but not toward lower scientific standards.

The review’s methods work and Recommendation 30 emphasise best-practice methods, data standardisation, standardised analytics and reporting, and transparent evidence development. Recommendation 35 on non-randomised and observational evidence also makes clear that newer evidence forms must be justified, that control methods need explanation, and that multiple approaches or data sources may be needed where appropriate.

In practical terms, credible RWE for HTA still needs to be fit for purpose. That means appropriate design, transparent protocols, reasonable control of confounding and bias, endpoints aligned to the decision problem, and data quality strong enough to support clinical and economic conclusions. So the Australian direction is not “RWE instead of rigour”; it is “RWE under conditions that make it decision-grade.” For industry, that means evidence planning has to become more deliberate. Good RWE will increasingly need to be designed, not improvised.

7. What is the significance of the proposed discount-rate change?

It is one of the clearest examples of the reform moving from abstract principle to concrete methodological change.

Recommendation 39 addresses the discount rate and recommends that Australia reduce the base-case discount rate to no lower than 3.5% for technologies with upfront costs and long-term benefits. This is particularly relevant to technologies such as some gene therapies and vaccines, where much of the value accrues far into the future. Under higher discounting, those future benefits are mathematically shrunk more aggressively, which can systematically disadvantage long-horizon technologies in cost-effectiveness models.

This matters because discounting is not just a technical curiosity; it can materially change an incremental cost-effectiveness ratio. For companies in advanced therapies, prevention, or technologies with durable outcomes, the proposed shift could improve the analytic visibility of long-term value. It also signals something broader: Australia is willing to revisit core methodological assumptions where older settings may no longer be appropriate for newer technology classes.

8. How seriously is the reform taking equity?

Much more seriously than many reforms that mention equity mainly in narrative terms.

Equity is one of the four explicit top-level aims of the review, and Recommendation 1 is especially important because it proposes a more equitable system for First Nations people, including the establishment of a First Nations Advisory Committee reporting to PBAC and MSAC. The recommendations summary also highlights inequities affecting children and people in rural and remote settings. So equity is being built into governance and process design, not just acknowledged as a general value.

This changes the strategic environment. Traditional HTA has often been strongest at measuring aggregate efficiency: average gain, overall cost-effectiveness, total budget impact. Equity introduces a different lens: who benefits, who is excluded by existing evidence norms, and whether some technologies deserve attention precisely because they address populations underserved by current pathways. For sponsors, this means equity claims — whether around First Nations health, paediatric need, rare disease, or remote access — may become more structurally relevant to the way evidence and value are interpreted.

9. What is actually happening now? Are these reforms live yet?

The reforms are in motion, but the system has not been fully rewritten yet.

The Implementation Advisory Group (IAG) was set up to analyse the 50 recommendations, advise on prioritisation and sequencing, and develop a roadmap. Its interim report says that early insights were consolidated into five focus areas: improved access and equity, greater transparency and engagement, modernised assessment pathways, better data and evidence, and HTA workforce capacity and capability. The same report also notes that it had been meeting regularly and was moving into prioritisation and roadmap development.

The right way to describe the current situation is this: the Australian rules are neither frozen nor fully remade. There is now a recognisable reform programme, but not every recommendation has been finally accepted and operationalised. For companies, this creates an important strategic window. Evidence strategies, stakeholder engagement and Australian launch thinking should be designed with the reform direction in mind, even where final procedural details are still emerging.

10. What should a MedTech, diagnostics or digital-health company actually do differently now?

The biggest change is conceptual: companies should stop thinking only in terms of a submission dossier and start thinking in terms of evidence architecture.

A traditional reimbursement mindset often focuses on getting a single package over the line at one moment in time. The reform implies a broader model. Pre-market evidence still matters, of course, but so do post-launch data plans, uncertainty-reduction strategies, managed evidence pathways, and the ability to explain pathway-level and equity-relevant value. A diagnostics company, for example, should not only present test accuracy; it should show how testing changes treatment choice, reduces waste, improves precision use of therapy, and may alter downstream cost and service use. An AI company should not only show model performance; it should demonstrate workflow fit, implementation conditions, and real-world service effects.

A useful concrete example is a biomarker-defined therapy plus companion diagnostic. The old model might focus mainly on the pivotal trial and a launch economic model. The newer model implied by this reform is more layered: pre-market evidence on diagnostic performance and comparative clinical utility, then post-launch registry or linked-data collection to monitor utilisation, subgroup outcomes, real-world effectiveness, and equity dimensions over time. That is the commercial meaning of Australia’s reform. It is not merely asking innovators for more evidence. It is asking them for a more intelligent, dynamic theory of value.

REFERENCES

Core Australian HTA Review sources

1. Australian Government Department of Health and Aged Care. Health Technology Assessment Policy and Methods Review – Final report. Canberra: Australian Government; 10 September 2024. Available at: https://www.health.gov.au/resources/publications/health-technology-assessment-policy-and-methods-review-final-report
2. Australian Government Department of Health and Aged Care. Health Technology Assessment Policy and Methods Review – Full recommendations. Canberra: Australian Government; 10 September 2024.​
3. Australian Government Department of Health and Aged Care. Health Technology Assessment Policy and Methods Review – Recommendations summary. Canberra: Australian Government; 10 September 2024.
4. Australian Government Department of Health and Aged Care. Health Technology Assessment Policy and Methods Review – Overview and updates. Including “Final reports of the HTA Policy and Methods Review and Enhanced Consumer Engagement Process.” PBS / Department web updates; September 2024.

Implementation, governance, and discount rate

5. Australian Government Department of Health and Aged Care. Health Technology Assessment Review – Implementation Advisory Group (IAG): Interim Report. Canberra: Australian Government; 6 August 2025 (published September 2025).​
6. Australian Government Department of Health and Aged Care. HTA Policy and Methods Review update. PBS news item; 2 December 2024. Describes the establishment and role of the HTA Review Implementation Advisory Group.​
7. Medicines Australia. Fact Sheet: Discount Rate – HTA Policy and Methods Review. Canberra: Medicines Australia; October 2024. Summarises Recommendation 39 on reducing the base‑case discount rate for technologies with long‑term benefits.​

Methods “engine room”: technical papers commissioned for the review

8. Australian Government Department of Health and Aged Care. HTA Methods: Economic Evaluation – Technical Paper for the Health Technology Assessment Policy and Methods Review. Canberra: Australian Government; July 2024.​
9. Australian Government Department of Health and Aged Care. Optimising the Availability and Use of Real‑World Data and Real‑World Evidence for HTA – Technical Paper for the HTA Policy and Methods Review. Canberra: Australian Government; July 2024.​
10. Australian Government Department of Health and Aged Care. Emerging Health Technologies – Technical Paper for the HTA Policy and Methods Review. Canberra: Australian Government; 2024. (Addresses methods issues for digital, AI, and precision technologies.)
11. Australian Government Department of Health and Aged Care. HTA Pathways and Timelines – Technical Paper for the HTA Policy and Methods Review. Canberra: Australian Government; 2024. (Examines process design, sequencing, and options for streamlined or parallel pathways.)

Key peer‑reviewed commentaries and empirical studies

12. Ramagopalan SV. Access in all areas? A round‑up of developments in market access and health technology assessment. International Journal of Technology Assessment in Health Care. 2025.
13. Gao Y, et al. Does Regulatory and Reimbursement Parallel Processing Provide Swifter Funded Access to Medicines? Evaluation of Cancer Medicines Using the Australian Parallel Process. Value in Health. 2025.​
14. Sellars M, Carter SM, Lancsar E, Howard K, Coast J. Making recommendations to subsidize new health technologies in Australia: A qualitative study of decision‑makers’ perspectives on committee processes. Health Policy. 2024.​
15. Nicod E, Kanavos P. Scientific and social value judgements in health technology assessment: a methodological review. International Journal of Technology Assessment in Health Care. 2016.
16. Cookson R, et al. Resource allocation, social values and the QALY. Health Economics. 2002;11(7):653–665.​
17. Killedar A, et al. Reflecting social values in HTA methods: a case study of equity‑informed deliberation. [Journal / in press, 2025] – Australian case study on incorporating equity into HTA deliberation.​

RWE and expanded value in HTA (global context)

18. Makady A, et al. Real‑world evidence to support health technology assessment: a position paper. [Journal] 2025.
19. Franklin JM, et al. Use of real‑world evidence in health technology assessment of pharmaceuticals. [Journal] 2024.
20. RTI Health Solutions. Rethinking Health Technology Assessment: Expanding Value Beyond Health Gains and Costs. RTI Health Solutions Insights; 2025.​
21. Husereau D, et al. Health technology assessment and economic evaluation: current practice and future challenges. F1000Research. 2018.​

Helpful secondary summaries for non‑specialist readers

22. Rare Voices Australia. Final Reports Published: Health Technology Assessment Policy and Methods Review and Enhanced Consumer Engagement Process. Stakeholder summary; 11 September 2024.​
23. Becaris Publishing. Review of Australian HTA policy and methods prioritizes real‑world evidence and equity. HTA blog post; September 2024.​
24. PBS / Department of Health and Aged Care. Updates to the HTA Policy and Methods Review Reference Committee. News item; 15 April 2024.​